Pharsight

1. Elepsia Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425938	TRIPOINT	Pharmaceutical composition	Feb, 2026 (1 year, 9 months from now)
US8535717	TRIPOINT	Pharmaceutical composition	Feb, 2026 (1 year, 9 months from now)
US8163306	TRIPOINT	Oral drug delivery system	Sep, 2027 (3 years from now)
US8431156	TRIPOINT	Pharmaceutical composition	Oct, 2027 (3 years from now)
US8470367	TRIPOINT	Oral drug delivery system	Oct, 2027 (3 years from now)

Market Authorisation Date: 20 December, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
1GM	TABLET, EXTENDED RELEASE;ORAL	Discontinued
1.5GM	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Application	Filing Date	Opposition Party	Legal Status

EP06776372A	2015-06-09	Cooke, Richard	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802142	UCB INC	Pharmaceutical compositions comprising levetiracetam and process for their preparation	Jun, 2031 (7 years from now)
US8802142 (Pediatric)	UCB INC	Pharmaceutical compositions comprising levetiracetam and process for their preparation	Dec, 2031 (7 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Dec 16, 2014
Pediatric Exclusivity(PED)	Jun 16, 2015

Market Authorisation Date: 06 January, 2006

Treatment: NA

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
250 mg, 500 mg and 750 mg
1000 mg	24 Jan, 2007	1	15 Jan, 2009	14 Jul, 2008

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858122	UCB INC	Extended release formulation of levetiracetam	Sep, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Sep 12, 2011

Market Authorisation Date: 12 September, 2008

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
500 mg and 750 mg	07 Jan, 2011	3	12 Sep, 2011	17 Sep, 2028	Eligible
1000 mg	07 Jan, 2011	2		17 Sep, 2028	Extinguished

Strength	Dosage	Availability
500MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
750MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463160	APRECIA PHARMS	Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same	Feb, 2018 (6 years ago)
US6471992	APRECIA PHARMS	Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same	Feb, 2018 (6 years ago)
US9669009	APRECIA PHARMS	Rapid disperse dosage form containing levetiracetam	Mar, 2034 (9 years from now)
US9339489	APRECIA PHARMS	Rapid disperse dosage form containing levetiracetam	Mar, 2034 (9 years from now)
US11160786	APRECIA PHARMS	Rapid disperse dosage form	Mar, 2034 (9 years from now)

Market Authorisation Date: 31 July, 2015

Treatment: Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam

Dosage: TABLET, FOR SUSPENSION;ORAL